Peregrine Pharmaceuticals (PPHM +15%) continue to rise ahead of its September 7 presentation at...


Peregrine Pharmaceuticals (PPHM +15%) continue to rise ahead of its September 7 presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, where the drug developer will present Phase II trial data for bavituximab, its drug candidate to treat non-small cell lung cancer.

From other sites
Comments (2)
  • pegasusken
    , contributor
    Comments (4) | Send Message
     
    looks like the recent pullback was an attempt to scare shares out of weak hands. Market manipulation? Hold on. This is some ride.
    5 Sep 2012, 07:09 PM Reply Like
  • LarryWh
    , contributor
    Comments (280) | Send Message
     
    For sure, the article by AF yesterday clearly impacted those that do not read or understand the details what is going. The most illogical assumption is the data being presented has no significance. This was a late entry, scrutinized by colleagues and has to meet exceptional cause for late submission. NOPE they must all be lying!
    7 Sep 2012, 11:19 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs